RefBan

Referral Banners

Yashi

Monday, March 17, 2014

Reuters Health Report

Click to View in Browser
03/17/2014
Reuters Election 2012 Daily round-up of the day's top news from the campaign trail, the White House and all the politics in between
U.S. says Obamacare covers married gay couples under family plan
WASHINGTON (Reuters) - Married gay couples will be eligible for a family health policy under President Barack Obama's healthcare reform law, beginning in 2015, the U.S. government said on Friday, encouraging insurers to begin offering coverage this year.
Riding with impaired drivers tied to riskier teen driving
NEW YORK (Reuters Health) - Teens who've been in cars with impaired drivers may be more likely themselves to get behind the wheel drunk or drugged, a recent study suggests. And the more times they're driven around by an impaired driver, the more risky their own driving habits become.
Attorneys general call on top U.S. retailers to drop tobacco products
(Reuters) - A group of 28 U.S. attorneys general is urging chief executive officers of five major retailers, including Walmart, to stop selling tobacco products, saying it is contradictory to carry such items in stores that also provide health care services.
FDA panel backs Staar Surgical's implantable lens
(Reuters) - Staar Surgical Co said an independent advisory panel to the U.S. Food and Drug Administration recommended marketing approval for its implantable vision-correction lens, sending the company's shares up 22 percent in premarket trade on Monday.
Amgen drug meets goal for those with high genetic cholesterol
(Reuters) - Amgen Inc said on Monday its experimental new type of cholesterol fighter met the primary goal of a late-stage trial by significantly cutting "bad" LDL cholesterol among patients with a genetic tendency towards very high levels of the artery clogging fat.
Fitness options multiply for the time-pressed and money-stressed
NEW YORK (Reuters) - Time, money and the Internet are changing where Americans work out, fitness experts say.
Intercept says liver disease drug effective in trial
NEW YORK (Reuters) - Intercept Pharmaceuticals Inc said on Sunday its experimental liver disease drug was effective in a third late-stage clinical trial and that the results set the stage for the company to file for marketing approval.
A plunge in U.S. preschool obesity? Not so fast, experts say
NEW YORK (Reuters) - If the news last month that the prevalence of obesity among American preschoolers had plunged 43 percent in a decade sounded too good to be true, that's because it probably was, researchers say.
Heart maker Carmat to wait before next transplant: founder
PARIS (Reuters) - French artificial heart maker Carmat will not carry out any more human transplants until it has determined the cause of the death of the first patient fitted with its device, one of the company's co-founders said on Sunday.
Insurers must accept funds from U.S. program that helps HIV-AIDs patients
NEW YORK (Reuters) - The lead agency for President Barack Obama's healthcare reform announced on Friday that it would require, rather than merely encourage, insurers that sell Obamacare policies to accept funds from a federal program that helps people with HIV-AIDS pay health insurance premiums.
Related Video
Nature's death knell: How a frog's love song is a bat's dinner bell
Scientists seek vaccine for deadly East Coast Fever
SUBSCRIBE TO OTHER REUTERS NEWSLETTERS
 Reuters Deals Today
The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today  
Reuters Business Today
A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today  
» MORE NEWSLETTERS
- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters
Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details
Subscribe to other Reuters newsletters.
Unsubscribe from this newsletter.
Follow us on Twitter facebook Friend us on Facebook Forward this newsletter to a friend Forward to a friend

No comments:

Yashi

Chitika